Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Lay Description
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Category
- Child Health
- Cancers and Other Neoplasms
- Acute Lymphoblasic Leukemia
- IRB Number
- 20180841HU
- NCT Number
- NCT02981628
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Between 1 Year and 21 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Anne-Marie Langevin
(210) 567-7460
langevin@uthscsa.edu
Principal Investigator
Anne-Marie Langevin